...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Free
AGORACOM NEWS FLASH

Dear Agoracom Family,

I want to thank all of you for your patience with us over the past 48 hours and apologize for what was admittedly a botched launch of our new site.

As you can see, we have reverted back to the previous version of the site while we address multiple forum functionality flaws that inexplicably made their way into the launch.

To this end:

1.We have identified 8 fundamental but easily fixable flaws that will be corrected in the coming week, so that you can continue to use the forums exactly as you've been accustomed to.

2.Additionally we will also be implementing a couple of design improvements to "tighten up" the look and feel of the forums.

Sincerely,

George et al

Message: Re: Competition from Constellation
Reply New Message
Back To Forum List View
Competition from Constellation
4
masila
Dec 13, 2017 09:01AM
Icon president Re: Competition from Constellation
4
BearDownAZ
Dec 13, 2017 04:21PM

Another company entering a study in this area.  It seems they have aspirations to enter not only mCRPC but also have something in pre-clinical for Triple Negative Breast Cancer - similar to Zenith plans.  It seems that their PCM-075 drug is targeting PLK1 enzyme. 

 

http://trovagene.investorroom.com/2017-12-14-Trovagene-Submits-Protocol-to-FDA-for-Phase-2-Clinical-Trial-of-PCM-075-in-Combination-with-Zytiga-R-for-Metastatic-Castration-Resistant-Prostate-Cancer 

 

 

TrovaGene (TROV) said Thursday it has filed the protocol for a phase 2 study of PCM-075 in combination with Johnson & Johnson's (JNJ) Zytiga for metastatic castration-resistant prostate cancer for review by the US Food and Drug Administration.

 

The company said the primary efficacy endpoint is the proportion of patients achieving disease control after 12 weeks of study treatment, as defined by lack of prostate specific antigen progression in patients who are showing signs of early progressive disease while currently receiving androgen deprivation therapy plus abiraterone and prednisone.

 

If the FDA allows the study to proceed, Trovagene plans to start it in 2018.

 

 

----------------

masila

3 Recommendations
Reply New Message
Back To Forum List View
Share
Share
New Message
Please login to post a reply